Oral delivery of Sunitinib malate using carboxymethyl cellulose/poly(acrylic acid-itaconic acid)/Cloisite 30B nanocomposite hydrogel as a pH-responsive carrier.

Autor: Sayyar Z; Department of Chemical Engineering, University of Bonab, Bonab, 55513-95133, Iran. z_sayyar@ubonab.ac.ir., Pakdel PM; Faculty of Chemical and Petroleum Engineering, University of Tabriz, Tabriz, 5166616471, Iran., Peighambardoust SJ; Faculty of Chemical and Petroleum Engineering, University of Tabriz, Tabriz, 5166616471, Iran. j.peighambardoust@tabrizu.ac.ir.
Jazyk: angličtina
Zdroj: BMC biotechnology [BMC Biotechnol] 2024 Sep 30; Vol. 24 (1), pp. 70. Date of Electronic Publication: 2024 Sep 30.
DOI: 10.1186/s12896-024-00883-0
Abstrakt: This work aimed to fabricate a Cloisite 30B-incorporated carboxymethyl cellulose graft copolymer of acrylic acid and itaconic acid hydrogel (Hyd) via a free radical polymerization method for controlled release of Sunitinib malate anticancer drug. The synthesized samples were characterized by FTIR, XRD, TEM, and SEM-dot mapping analyses. The encapsulation efficiency of Hyd and Hyd/Cloisite 30B (6 wt%) was 81 and 93%, respectively, showing the effectiveness of Cloisite 30B in drug loading. An in vitro drug release study showed that drug release from all samples in a buffer solution with pH 7.4 was higher than in a buffer solution with pH 5.5. During 240 min, the cumulative drug release from Hyd/Cloisite 30B (94.97% at pH 7.4) is lower than Hyd (53.71% at pH 7.4). Also, drug-loaded Hyd/Cloisite 30B (6 wt%) demonstrated better antibacterial activity towards S. Aureus bacteria and E. Coli. High anticancer activity of Hyd/Cloisite 30B against MCF-7 human breast cancer cells was shown by the MTT assay, with a MCF-7 cell viability of 23.82 ± 1.23% after 72-hour incubation. Our results suggest that Hyd/Cloisite 30B could be used as a pH-controlled carrier to deliver anticancer Sunitinib malate.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: